Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
3D Culture/Scaffold

Stem Cell Related Patent Number US5698765

Title:Mouse having a disrupted CD4 gene
Inventors:Mak, Tak W.; Toronto, Canada
Summary:This invention introduces a mouse homozygous for a disrupted CD4 gene, methods and uses thereof. Described herein is a mutant mouse strain without CD4 expression, such that the CD4 gene has been disrupted by a selectable marker sequence, wherein the disruption prevents the expression of the CD4 cell surface antigen. The mouse is further characterized by a lack of CD4+ T lymphocytes in peripheral lymphoid organs, while the development of CD8+ thymocytes and myeloid components remains unaltered. Claims of the invention include decreased helper cell activity for antibody responses in such mice, whereas cytotoxic T cell activity against viruses remains within the normal range of that generated by CD4+ mice. Experimental applications are included for the use of such mice as a research model.
Abstract:A mutant mouse strain without CD4 expression has been generated by disrupting the CD4 gene using embryonic stem cell technology. In these mice CD4.sup.+ T lymphocytes are not present in peripheral lymphoid organs, but the development of CD8.sup.+ T cells and myeloid components is unaltered, indicating that expression of CD4.sup.+ on progenitor cells and CD4.sup.+ CD8.sup.+ (double positive) thymocytes is not obligatory. These mice have markedly decreased helper cell activity for antibody responses, whereas cytotoxic T cell activity against viruses was within normal range of that generated by CD4.sup.+ mice. This differential requirement for CD4.sup.+ helper T cells has important implications for the understanding of the immune function in a variety of immune disorders, including AIDS, in which the CD4.sup.+ cells are reduced or absent.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5698765
Application Number:US1995000400173
Date Filed:06/03/1995
Date Published:16/12/1997
Assignee:The Ontario Cancer Institute, Toronto, Canada

Copyright © 2007 The Institute for Cellular Medicine  10/1/2022